Director/PDMR Shareholding

RNS Number : 7997G

Eden Research plc

28 July 2021

 

28 July 2021

Eden Research plc

("Eden" or "Company")

Director/PDMR Shareholding

Eden Research plc (AIM: EDEN), the AIM-quoted company focused on sustainable biopesticides and plastic-free formulation technology for use in global crop protection, animal health and consumer products industries, announces that Sean Smith, CEO, has purchased 180,000 shares in Eden at a price of £0.10 per share.

Following the transaction outlined above, Mr. Smith's interest in the share capital of the Company is 911,039 Ordinary Shares representing 0.24 per cent. of the Company's issued share capital. 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

For further information contact:

Eden Research plc	www.edenresearch.com
Sean Smith Alex Abrey	01285 359 555
Cenkos Securities plc (Nominated advisor and broker)
Giles Balleny / Camilla Hume/ Mark Connelly  (corporate finance) Michael Johnson (sales)	020 7397 8900
Hawthorn Advisors (Financial PR)
Lorna Cobbett / Victoria Ainsworth	[e-mail]

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Sean Smith
2	Reason for the notification
a)	Position/status	Chief Executive Officer
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Eden Research plc
b)	LEI	213800ZWTYTVQQSM3J85
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 1 pence each GB0001646941
b)	Nature of the transaction	Purchase of Ordinary Shares
c)	Price(s) and volume(s)	Price(s) Volume(s) 10.00p 180,000
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	28 July 2021
f)	Place of the transaction	LSE, AIM Market (XLON)

Notes to Editors:

Eden Research is an AIM quoted company that develops and supplies breakthrough biopesticide products and natural, plastic-free microencapsulation technologies to the global crop protection, animal health and consumer products industries.

Eden's Sustaine® encapsulation technology is used to harness the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. Sustaine microcapsules are naturally derived, plastic-free, biodegradable micro-spheres derived from yeast extract. It is one of the only viable, proven and immediately registerable solutions to the microplastics problem in formulations requiring encapsulation.

Eden has numerous patents and a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. Eden was admitted to trading on AIM in May 2012.

For more information about Eden, please visit: www.edenresearch.com.

 

END

 

 

DSHSEFFDAEFSEIW